Spyre Therapeutics develops long-acting antibody therapies and antibody combinations for inflammatory bowel disease and rheumatic diseases. The company’s pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A and IL-23, with programs such as SPY001, SPY002 and SPY003 evaluated as monotherapies and pairwise combinations.
Recurring news for Spyre Therapeutics includes clinical updates from the SKYLINE platform trial in ulcerative colitis and the SKYWAY basket trial in rheumatic diseases, financial results and corporate updates, common-stock financing activity, and equity inducement awards under its 2018 Equity Inducement Plan. Company announcements also describe balance-sheet actions, development priorities and data presentations tied to its immune-mediated disease pipeline.
Spyre Therapeutics (Nasdaq: SYRE) announced the closing of an underwritten public offering on Oct 15, 2025 of 17,094,594 shares of common stock, including the full exercise of a 2,229,729‑share underwriter option, at $18.50 per share. The offering generated approximately $316.2 million in gross proceeds before underwriting discounts, commissions and offering expenses. A Form S‑3 registration (File No. 333‑285341) became effective on Mar 7, 2025. Joint book‑running managers included Jefferies, TD Securities, Leerink Partners and Stifel; Wedbush acted as lead manager.
Spyre Therapeutics (NASDAQ: SYRE) priced an underwritten public offering of 14,864,865 common shares at $18.50 per share, expected to generate approximately $275.0 million in gross proceeds before underwriting discounts, commissions and offering expenses. The company also granted underwriters a 30-day option to purchase up to an additional 2,229,729 shares at the public offering price.
The offering is expected to close on or about October 15, 2025, subject to customary closing conditions. A registration statement (Form S-3, File No. 333-285341) became effective on March 7, 2025.
Spyre Therapeutics (Nasdaq: SYRE) announced on Oct 13, 2025 that it has commenced an underwritten public offering of shares of common stock and, for certain investors, pre-funded warrants to purchase common stock. All securities in the offering will be sold by Spyre. The company expects to grant underwriters a 30-day option to buy additional shares at the public offering price, less underwriting discount. The offering is subject to market and other conditions, and the final terms will be disclosed in a prospectus supplement filed with the SEC (Form S-3 File No. 333-285341).
Spyre Therapeutics (NASDAQ: SYRE) announced poster presentations at United European Gastroenterology Week (UEGW) 2025, according to the PR dated Oct 5, 2025.
The PR states interim Phase 1 data for SPY002 show it was well tolerated through six months, has a differentiated PK profile that the company says could support quarterly (Q3M) or twice‑yearly (Q6M) dosing, and suppressed free TL1A through 24 weeks. The company also reported preclinical combination data where α4β7 + TL1A, α4β7 + IL‑23, and TL1A + IL‑23 combinations outperformed monotherapies in rodent TNBS colitis models. Posters and session details are available via the UEGW program, per the PR.
Spyre Therapeutics (NASDAQ: SYRE) announced on Oct 3, 2025 that its independent Compensation Committee approved inducement stock option awards to three non-executive employees under the 2018 Equity Inducement Plan.
The awards, approved on Oct 1, 2025, total 42,500 options with a 10-year term and an exercise price of $16.46—the Nasdaq closing price on Oct 1, 2025. Options vest 25% on the first anniversary of each employee’s start date and then monthly at 1/48th thereafter, subject to continued service, and remain subject to the terms of the 2018 Plan.
Spyre Therapeutics (NASDAQ: SYRE) has initiated dosing in its Phase 2 SKYWAY basket trial for SPY072, their pioneering anti-TL1A antibody targeting rheumatic diseases. The trial focuses on treating patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA).
SPY072 is designed for superior potency and convenience, with potential for quarterly or twice-yearly subcutaneous maintenance dosing. The SKYWAY trial, alongside the SKYLINE study, is expected to provide 9 proof-of-concept readouts in 2026-27. The company targets commercial markets exceeding $60B in annual revenue, with topline data expected in 2026.
Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotech company focused on developing antibody treatments for Inflammatory Bowel Disease (IBD) and other immune-mediated diseases, has announced its participation in two major healthcare investor conferences in June 2025.
The company will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 8:10am ET, and the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, at 9:20am ET. Live webcasts and replays will be accessible through Spyre's investor relations website.